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ABSTRACT 
 
Objective: To estimate the patient-specific risk of preeclampsia (PE) at 35-37 weeks’ 
gestation by a combination of maternal characteristics and medical history with multiple of 
the median (MoM) values of mean arterial pressure (MAP), uterine artery pulsatility index 
(UTPI), serum placental growth factor (PLGF) and serum soluble fms-like tyrosine 
kinase-1 (sFLT-1) and stratify women into high-, intermediate- and low-risk management 
groups. 
 
Methods: This was a prospective observational study in women attending for a 
third-trimester ultrasound scan at 35-37 weeks as part of routine pregnancy care. 
Patient-specific risks of delivery with PE at <4 weeks from assessment and PE at <42 
weeks’ gestation were calculated using the competing risks model to combine the prior 
risk from maternal characteristics and medical history with MoM values of MAP, UTPI, 
PLGF and sFLT-1. On the basis of these risks the population was stratified into high-, 
This article is protected by copyright. All rights reserved.
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1002/uog.17419 
  
A
cc
ep
te
d 
A
rti
cl
e
intermediate- and low-risk groups. Different risk cut-offs were used to vary the proportion 
of the population stratified into each risk category and the performance of screening for 
delivery with PE at <40 and >40 weeks’ gestation was estimated.  
 
Results: The study population of 3,703 singleton pregnancies included 38 (1.0%) with PE 
at <40 weeks’ gestation and 22 (0.6%) with PE at >40 weeks. Using a risk cut-off for PE 
at <4 weeks of 1 in 50 to define the high-risk group and a risk cut-off of <1 in 100 for PE at 
<42 weeks’ gestation to define the low-risk group, the proportion of the population 
stratified into high-, intermediate- and low-risk was about 12.7%, 28.8% and 58.5%, 
respectively. The high-risk group contained 92% of pregnancies with PE at <40 weeks’ 
gestation and 73% of those with PE at >40 weeks. The intermediate-risk group contained 
a further 27% of women with PE at >40 weeks. In the low-risk group, none of the women 
developed PE at <40 or >40 weeks’ gestation. 
 
Conclusion: The study presents risk stratification of PE by the combined test at 35-37 
weeks aiming to identify a high-risk group in need of intensive monitoring from the time of 
the initial assessment and up to 40 weeks’ gestation, an intermediate-risk group in need 
of reassessment at 40 weeks’ gestation and a low-risk group which can be reassured that 
they are unlikely to develop PE.    
This article is protected by copyright. All rights reserved.
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Introduction 
 
In the traditional approach to prenatal care, screening and diagnosis of preeclampsia (PE) 
is based on the demonstration of elevated blood pressure and proteinuria during a routine 
clinical visit in the late second- or third-trimester of pregnancy. In a proposed new pyramid 
of pregnancy care, the timing and content of clinical visits should be defined by the 
patient-specific risk of developing PE.1 The objectives of screening for PE are firstly, to 
reduce the prevalence of the disease through pharmacological intervention in the high-risk 
group identified in the first-trimester of pregnancy 2,3 and secondly, to minimize adverse 
perinatal events for those that develop PE by determining the appropriate time and place 
for delivery.4 The second objective can be potentially achieved through risk stratification in 
the second and / or third-trimester of pregnancy.  
 
Screening for term-PE by a combination of maternal factors with multiples of the median 
(MoM) values of mean arterial pressure (MAP), uterine artery pulsatility index (UTPI), 
serum placental growth factor (PLGF) and serum soluble fms-like tyrosine kinase-1 
(sFLT-1) at 35-37 weeks’ gestation predicted about 85% of affected pregnancies, at false 
positive rate of 10% and this performance is superior to that achieved by screening at 
11-13, 19-24 or 30-34 weeks with respective detection rates of 47%, 46% and 66%.5-9  
 
The objective of this study is to estimate the patient-specific risk of PE at 35-37 weeks’ 
gestation by a combination of maternal characteristics and medical history with MAP, 
UTPI, PLGF and sFLT-1 and stratify women into high-, intermediate- and low-risk 
management groups. The high-risk group would require intensive monitoring from the 
time of the initial assessment and up to 40 weeks’ gestation, the intermediate-risk group 
would require reassessment at 40 weeks and the low-risk could be reassured that they 
are unlikely to develop PE. 
 
 
Methods 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for a third-trimester routine hospital visit at 35-37 weeks’ 
gestation at King’s College Hospital, London or Medway Maritime Hospital, Gillingham, 
UK between February and December 2014. In this visit we first, recorded maternal 
demographic characteristics and medical history, second, carried out an ultrasound 
examination for fetal anatomy and growth, third, measured the left and right UTPI by 
transabdominal color Doppler ultrasound and calculated the mean value of the two 
arteries,10 fourth, measured the MAP by validated automated devices and a standardized 
protocol11 and fifth, measured serum concentration of PLGF and sFLT-1 by an automated 
biochemical analyzer within 10 minutes of blood sampling (Cobas e411 system, Roche 
Diagnostics, Penzberg, Germany). Gestational age was determined by the measurement 
of fetal crown-rump length at 11-13 weeks or the fetal head circumference at 19-24 
weeks.12,13 
 
The women gave written informed consent to participate in the study, which was 
approved by the NHS Research Ethics Committee. The inclusion criteria for this study 
were singleton pregnancies delivering non-malformed live birth or stillbirth at >35 weeks’ 
gestation. We excluded pregnancies with aneuploidies and major fetal abnormalities. The 
study population is the same as in our previous report,6 but included pregnancies with 
measurements of all four biomarkers at 35+0-36+6 weeks.  
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Data on pregnancy outcome were collected from the hospital maternity records or the 
general medical practitioners of the women. The obstetric records of all women with 
pre-existing or pregnancy associated hypertension were examined to determine if the 
condition was PE, as defined by the International Society for the Study of Hypertension in 
Pregnancy.14  
 
In order to focus clinical resources effectively, we investigated a policy whereby 
pregnancies assessed for PE at 35-37 weeks are stratified into three groups (Figure 1). A 
group at high-risk for delivery with PE within 4 weeks of assessment (PE <4 weeks), 
would require intensive monitoring from the time of the initial assessment and up to 40 
weeks’ gestation; this group should be ideally small and contain a large proportion of 
pregnancies with PE at <40 weeks’ gestation. Conversely, the low-risk group, that would 
have no further assessment, should be large and contain very few pregnancies that 
develop PE at <40 or >40 weeks’ gestation. The intermediate-risk group, would ideally 
contain very few pregnancies with PE at <40 weeks’ gestation and a large proportion of 
pregnancies that deliver with PE >40 weeks; this group would require reassessment at 40 
weeks’ gestation.  
 
Statistical analysis 
 
Patient-specific risks of delivery with PE at <4 weeks from assessment and PE at <42 
weeks’ gestation were calculated using the competing risks model to combine the prior 
risk for PE from maternal characteristics and medical history with MoM values of MAP, 
UTPI, PLGF and sFLT-1.5,15-18 Pregnancies were allocated to the high-risk group if their 
risk for PE at <4 weeks was above a specific high-risk threshold and they were allocated 
to the low-risk group if their risk for PE at <42 weeks’ gestation was below a specified 
low-risk threshold. Otherwise, they were allocated to the intermediate-risk group. 
Performance was assessed in terms of the distribution of pregnancy outcomes by risk 
group.     
 
The statistical software package R was used for data analyses.19 
 
 
Results 
 
The study population of 3,703 singleton pregnancies included 38 (1.0%) with PE at <40 
weeks’ gestation and 22 (0.6%) with PE at >40 weeks; maternal and pregnancy 
characteristics are summarized in Table 1. The performance of screening for delivery with 
PE at >40 weeks’ gestation is poorer than that of screening for delivery with PE at <40 
weeks (Figure 2); the area under the receiver operating characteristic curve for PE at <40 
weeks was 0.953, 95% CI 0.913-0.993 and for PE at >40 weeks was 0.887, 95% CI 
0.840-0.933. This is the consequence of lower deviation from normal for each biomarker 
with increasing interval between assessment and delivery with PE.6 
 
The allocation of pregnancies to high-, intermediate- and low-risk groups according to the 
estimated risk for PE at <4 weeks and PE at <42 weeks’ gestation is given in Table 2. 
 
At risk cut-off for PE at <4 weeks of 1 in 10, 4.0% of pregnancies were allocated to the 
high-risk group and these contained 73.7% of pregnancies with PE at <40 weeks’ 
gestation and 18.2% of pregnancies with PE at >40 weeks’ gestation. The proportion of 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
the population classified as high-risk varied according to the risk cut-off for PE at <4 
weeks from 1.1% for cut-off of 1 in 3 to 12.7% for cut-off of 1 in 50 and the positive 
predictive value for PE at <40 weeks’ gestation ranged from 28.6% (12/42) to 7.4% 
(35/472). 
 
At a risk of <1 in 100 for PE at <42 weeks’ gestation, 58.5% of pregnancies were 
allocated to the low-risk group; in this group there were no cases of PE at <40 or >40 
weeks’ gestation and therefore, the negative predictive value for PE was 100%. 
 
At a risk cut-off of 1 in 50 for PE at <4 weeks and risk cut-off of 1 in 100 for PE at <42 
weeks’ gestation, 28.8% of pregnancies were allocated to the intermediate-risk group and 
these contained 7.9% of pregnancies with PE at <40 weeks’ gestation and 27.3% of 
pregnancies with PE at >40 weeks’ gestation. Consequently, for these particular risk 
cut-offs, 41.5% of pregnancies were allocated to the high- or intermediate-risk group and 
the combination of these groups contained all 22 of pregnancies with PE at >40 weeks’ 
gestation. 
 
 
Discussion 
 
Main findings 
 
The study has demonstrated an approach for stratification of the population into three 
management groups based on the estimated risk for PE at <4 weeks from assessment 
and PE at <42 weeks’ gestation by a combination of maternal factors, MAP, UTPI, PLGF 
and sFLT-1 at 35-37 weeks’ gestation. A high-risk group would require intensive 
monitoring from the time of the initial assessment and up to 40 weeks’ gestation, an 
intermediate-risk group, together with those pregnancies in the high-risk group that had 
not yet delivered, would require reassessment at 40 weeks’ gestation to decide the best 
time and method of delivery and a low-risk group would be managed expectantly.  
 
The proportion of the population stratified into high- intermediate- and low-risk groups and 
the proportion of each strata delivering with PE at <40 and >40 weeks’ gestation would 
inevitably depend on the risk cut-offs used for defining the groups. At estimated risk 
cut-off of 1 in 50 for PE at <4 weeks to define the high-risk group and risk of <1 in 100 for 
PE at <42 weeks’ gestation to define the low-risk group, 12.7%, 28.8% and 58.5% of 
pregnancies were allocated to the high-, intermediate- and low-risk groups, respectively. 
The high-risk group contained 92.1% of pregnancies with PE at <40 weeks’ gestation and 
the combined high- and intermediate-risk groups contained all pregnancies with PE 
at >40 weeks’ gestation. In the low-risk group there were no cases of PE at <40 or >40 
weeks’ gestation. 
 
Strengths and limitations 
 
The strengths of this late third-trimester screening study for PE are first, examination of 
pregnant women attending for routine assessment of fetal growth and wellbeing, second, 
recording of data on maternal characteristics and medical history to define the prior risk, 
third, use of a specific methodology and appropriately trained doctors to measure MAP 
and UTPI, fourth, use of automated machines to provide accurate measurement within 40 
minutes of sampling of maternal serum concentration of PLGF and sFLT-1, fifth, 
expression of the values of the biomarkers as MoMs after adjustment for factors that 
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affect the measurements, and sixth, use of Bayes theorem to combine the prior risk from 
maternal factors with biomarkers to estimate patient-specific risks and stratify women into 
high-, intermediate- and low-risk management groups. 
 
A limitation of the study is that fitting of the risk model 6 and development and assessment 
of risk stratification were on the same data, which induces a degree of optimistic bias into 
the results. However, our risk model 6 is a parsimonious one with just two parameters for 
the mean log MoM value for each of the markers and a pooled estimate of an assumed 
common covariance matrix and this limits the degree of bias induced. Nevertheless, 
prospective evaluation using an independent test data set is needed to validate the 
results.   
 
Comparison with previous studies 
 
In a previous study at 35-37 weeks’ gestation we presented the results on the 
performance of screening in a routine population by maternal factors and MAP, UTPI, 
PLGF and sFLT-1.6 This study investigated a policy whereby pregnancies assessed for 
PE at 35-37 weeks are stratified into risk groups for subsequent pregnancy management.  
A previous study reported on a policy whereby pregnancies assessed for PE at 30-34 
weeks are stratified into risk groups for subsequent pregnancy management.20  
 
Clinical implications of the study 
 
The performance of screening for term-PE by a combination of maternal factors with 
biomarkers at 12, 22 or 32 weeks’ gestation is relatively poor compared to screening at 
36 weeks 5-9 and we have therefore proposed that all women, irrespective of whether they 
had prior screening or not, should have assessment of risk at 35-37 weeks.6  
 
This study provides the framework for stratification of risk for PE based on screening at 
35-37 weeks. In all pregnancies, the routine ultrasound examination carried out at 35-37 
weeks would have already identified any possible impairment of fetal growth and in such 
case the decision on timing of delivery would be based on fetal heart rate patterns and / 
or Doppler findings in the umbilical artery, middle cerebral artery and ductus venosus. 
The group classified as being at high-risk for PE can be monitored by measurement of 
blood pressure and urinalysis at least on a weekly basis and the women can be advised 
to report any of the symptoms associated with severe PE, such as visual disturbance and 
epigastric pain. The intermediate-risk group, require reassessment at 40 weeks’ gestation 
but these women would also be advised to report any symptoms associated with severe 
PE. The low-risk group can be reassured that development of PE is very unlikely and in 
the absence of any abnormal ultrasound findings or other obstetric indications the 
pregnancies can be managed expectantly awaiting for spontaneous onset of labor. 
 
The cut-offs in risks to define the proportion of the population stratified into each of the 
three management groups and the protocols for such management will inevitably vary 
according to local preferences and health economic considerations. Future studies will 
examine whether the implementation of such protocols could improve perinatal outcome. 
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Figure legends 
 
Figure 1. Stratification of pregnancies into high-, intermediate- and low-risk management 
groups based on the estimated risk for preeclampsia at 35-37 weeks’ gestation. The 
high-risk group would require intensive monitoring from the time of the initial assessment 
and up to 40 weeks’ gestation, the intermediate-risk group would require reassessment at 
40 weeks’ gestation and the low-risk group would be managed expectantly.  
 
 
Figure 2. Receiver operating characteristic curves for prediction of delivery with 
preeclampsia at <40 weeks’ gestation (red curve) and at >40 weeks (blue curve) by 
combined screening at 35-37 weeks’ gestation. 
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Table 1. Maternal and pregnancy characteristics of the study population. 
 
Maternal characteristics 
Preeclampsia 
None (n=3,643) <40 w (n=38) >40 w (n=22) 
Age, median (IQR) 31.7 (26.8-35.3) 33.4 (27.7-36.4) 34.1 (30.5-36.0) 
Weight, median (IQR) 78.7 (70.6-89.3) 83.0 (74.4-98.7) 86.1 (81.3-98.3) 
Height, median (IQR) 1.64 (1.60-1.69) 1.65 (1.62-1.71) 1.64 (1.61-1.72) 
Racial origin    
     Caucasian, n (%) 2,709 (74.4) 26 (68.4) 19 (86.4) 
     Afro-Caribbean, n (%) 615 (16.9) 7 (18.4) 2 (9.1) 
     South Asian, n (%) 132 (3.6) 2 (5.3) 1 (4.5) 
     East Asian, n (%) 76 (2.1) 0 0 
     Mixed, n (%) 111 (3.0) 3 (7.9) 0 
Method of conception    
     Spontaneous, n (%) 3,538 (97.1) 35 (92.1) 20 (90.9) 
     Assisted conception, n (%) 105 (2.9) 3 (7.9) 2 (9.1) 
Cigarette smoking, n (%) 352 (9.7) 2 (5.3) 1 (4.5) 
Chronic hypertension, n (%) 44 (1.2) 2 (5.3) 1 (4.5) 
SLE / APS, n (%) 11 (0.3) 0 0 
Diabetes mellitus, n (%) 43 (1.2) 2 (5.3) 0 
Parity    
     Nulliparous, n (%) 1,797 (49.3) 26 (68.4) 19 (86.4) 
     Parous no previous PE, n (%) 1,773 (48.7) 7 (18.4) 2 (9.1) 
     Parous previous PE, n (%) 73 (2.0) 5 (13.2) 1 (4.5) 
Inter-pregnancy interval, median (IQR)¥ 3.1 (2.1-5.0) 4.9 (2.3-10.9) 2.9 
 
¥ Inter-pregnancy interval reported for parous women 
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Table 2. Proportion of the population stratified into high- intermediate- and low-risk 
groups based on the risk for preeclampsia (PE) at <4 weeks from assessment (PE <4w) 
and PE at <42 weeks’ gestation (PE <42GW) by a combination of maternal factors, MAP, 
UTPI, PLGF and sFLT-1 at 35-37 weeks’ gestation. 
 
Risk cut-off for PE 
Strata PE with delivery at: 
Type Size (n=3,703) <40 weeks (n=38) >40 weeks (n=22) 
1 in 3 for PE <4w and 
1 in 50 for PE <42 GW 
High 42 (1.1; 0.8, 1.5) 12 (31.6; 17.5, 48.7) 1 (4.5; 0.1, 22.8) 
Intermediate 980 (26.5; 25, 27.9) 25 (65.8; 48.6, 80.4) 20 (90.9; 70.8, 98.9) 
Low 2681 (72.4; 70.9, 73.8) 1 (2.6; 0.1, 13.8) 1 (4.5; 0.1, 22.8) 
1 in 3 for PE <4w and 
1 in 100 for PE <42 GW 
High 42 (1.1; 0.8, 1.5) 12 (31.6; 17.5, 48.7) 1 (4.5; 0.1, 22.8) 
Intermediate 1496 (40.4; 38.8, 42.0) 26 (68.4; 51.3, 82.5) 21 (95.5; 77.2, 99.9) 
Low 2165 (58.5; 56.9, 60.1) 0 (0; 0, 9.3) 0 (0; 0, 15.4) 
1 in 10 for PE <4w and 
1 in 50 for PE <42 GW 
High 148 (4.0; 3.4, 4.7) 28 (73.7; 56.9, 86.6) 4 (18.2; 5.2, 40.3) 
Intermediate 874 (23.6; 22.2, 25.0) 9 (23.7; 11.4, 40.2) 17 (77.3; 54.6, 92.2) 
Low 2681 (72.4; 70.9, 73.8) 1 (2.6; 0.1, 13.8) 1 (4.5; 0.1, 22.8) 
1 in 10 for PE <4w and 
1 in 100 for PE <42 GW 
High 148 (4.0; 3.4, 4.7) 28 (73.7; 56.9, 86.6) 4 (18.2; 5.2, 40.3) 
Intermediate 1390 (37.5; 36.0, 39.1) 10 (26.3; 13.4, 43.1) 18 (81.8; 59.7, 94.8) 
Low 2165 (58.5; 56.9, 60.1) 0 (0; 0, 9.3) 0 (0; 0, 15.4) 
1 in 20 for PE <4w and 
1 in 50 for PE <42 GW 
High 250 (6.8; 6.0, 7.6) 32 (84.2; 68.7, 94) 10 (45.5; 24.4, 67.8) 
Intermediate 772 (20.8; 19.5, 22.2) 5 (13.2; 4.4, 28.1) 11 (50.0; 28.2, 71.8) 
Low 2681 (72.4; 70.9, 73.8) 1 (2.6; 0.1, 13.8) 1 (4.5; 0.1, 22.8) 
1 in 20 for PE <4w and 
1 in 100 for PE <42 GW 
High 250 (6.8; 6.0, 7.6) 32 (84.2; 68.7, 94.0) 10 (45.5; 24.4, 67.8) 
Intermediate 1288 (34.8; 33.2, 36.3) 6 (15.8; 6.0, 31.3) 12 (54.5; 32.2, 75.6) 
Low 2165 (58.5; 56.9, 60.1) 0 (0; 0, 9.3) 0 (0; 0, 15.4) 
1 in 25 for PE <4w and 
1 in 50 for PE <42 GW 
High 292 (7.9; 7.0, 8.8) 33 (86.8; 71.9, 95.6) 10 (45.5; 24.4, 67.8) 
Intermediate 730 (19.7; 18.4, 21.0) 4 (10.5; 2.9, 24.8) 11 (50.0; 28.2, 71.8) 
Low 2681 (72.4; 70.9, 73.8) 1 (2.6; 0.1, 13.8) 1 (4.5; 0.1, 22.8) 
1 in 25 for PE <4w and 
1 in 100 for PE <42 GW 
High 292 (7.9; 7.0, 8.8) 33 (86.8; 71.9, 95.6) 10 (45.5; 24.4, 67.8) 
Intermediate 1246 (33.6; 32.1, 35.2) 5 (13.2; 4.4, 28.1) 12 (54.5; 32.2, 75.6) 
Low 2165 (58.5; 56.9, 60.1) 0 (0; 0, 9.3) 0 (0; 0, 15.4) 
1 in 50 for PE <4w and 
1 in 50 for PE <42 GW 
High 472 (12.7; 11.7, 13.9) 35 (92.1; 78.6, 98.3) 16 (72.7; 49.8, 89.3) 
Intermediate 550 (14.9; 13.7, 16.0) 2 (5.3; 0.6, 17.7) 5 (22.7; 7.8, 45.4) 
Low 2681 (72.4; 70.9, 73.8) 1 (2.6; 0.1, 13.8) 1 (4.5; 0.1, 22.8) 
1 in 50 for PE <4w and 
1 in 100 for PE <42 GW 
High 472 (12.7; 11.7, 13.9) 35 (92.1; 78.6, 98.3) 16 (72.7; 49.8, 89.3) 
Intermediate 1066 (28.8; 27.3, 30.3) 3 (7.9; 1.7, 21.4) 6 (27.3; 10.7, 50.2) 
Low 2165 (58.5; 56.9, 60.1) 0 (0; 0, 9.3) 0 (0; 0, 15.4) 
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Screening at 35-37 weeks’ gestation
Intermediate-riskHigh-risk Low- risk
Figure 1
Assessment at 40 weeks’ gestation
Monitoring starts 
immediately and 
continues to 40 
weeks’ gestation
Nothing else
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